IUA supports the securing of a strong outcome for research in the EU-UK future relationship: Reaching an agreement on UK participation in Horizon Europe

The EU and UK have been discussing UK participation in Union Programmes, including Horizon Europe, as part of the negotiations on a future EU-UK relationship. It is encouraging that both sides have committed to the principle of UK participation in their mandates, recognising that collaboration between the UK and the EU in the framework programmes strengthens our ability to tackle shared challenges, such as cancer and climate change.
It is vital that this commitment now translates quickly into an agreement on the terms of participation. Horizon Europe association should be a core part of the future relationship between the EU and the UK for research, underpinning valuable scientific partnerships that have been built up over many years.

We have all reaped the health benefits of these collaborations. Clinical trials, particularly on diseases with limited patient populations, are reliant on EU-UK collaboration, while close research partnerships continue to accelerate life-changing medical research. Our ability to respond to the threat of climate change and outbreaks of new diseases like Covid-19 has also been greatly improved by close scientific and clinical partnerships across Europe.
Knowledge and discovery do not stop at borders, and the shared global challenges we face require joint solutions. Collaboration through the research framework programmes is a springboard to productive partnerships across the world. We owe it to future generations in the UK, the EU and beyond to ensure that the new EU-UK relationship best serves them through research.

We call on both sides to continue these negotiations with fresh energy, a spirit of compromise, and a focus on what is needed for the success of the programme. To that end, we have identified a number of solutions to some of the sticking points in Horizon Europe discussions, which are set out in more detail below. These issues are:

• Demonstrating commitment to the programme
• Ensuring a fair financial contribution through a ‘two-way’ correction mechanism
• Accepting EU oversight of the use of programme funds
• Agreeing to introduce reciprocal mobility arrangements to support the programme
• Clarifying that the results of research can be exploited beyond the EU

Whatever solutions the negotiators choose to settle on, they should seek to come to an agreement quickly. Rapid progress is needed in the coming weeks if productive research collaborations are to continue smoothly into 2021, when the Horizon Europe programme begins.

Horizon Europe presents a key opportunity for EU and UK research communities, and agreement on association can be reached through strategic, sensible and pragmatic compromise. With enough will on both sides it should be possible to reach an agreement in the time available—but time is running out. The UK and EU research community is counting on negotiators to find a way forward in the coming weeks, for the benefit that research brings to citizens across the world.

1. Demonstrating commitment to the programme
It is reasonable for the EU to expect the UK to commit to the programme, and to work together to find an appropriate basis for participation. Conversely, it is reasonable for the UK to explore in parallel the alternative steps it would take if full association cannot be agreed, much as that outcome should be avoided. This should not be interpreted as a lack of commitment to the programme.

• To build trust, the UK should explicitly set aside additional funding for full association for Horizon Europe in its science budget, in the same way that other countries are doing as they begin their association discussions. Discussion of exit clauses for the agreement should proceed on the basis of Horizon 2020 precedents.

2. Financial contributions
The UK government should accept that it can no longer be a net beneficiary of the programme, and that it should pay a reasonable fee to cover administrative costs. This is a necessary and reasonable consequence of no longer being a Member State. The benefits of association are not purely financial and a significant value should be placed on the intangible benefits of association, which include access to networks and infrastructure, and operating at a scale, ambition, and associated risk level beyond what could be achieved bilaterally. Many other third countries recognise this and make overall net financial contributions to Horizon 2020 so that they can also play in the ‘Champions League’ of research funding schemes.

However, the current proposals are likely to create a financial imbalance that would be too much for the UK to reasonably pay, with no limit to how large this imbalance could become.

The current EU text includes a ‘one-way’ correction mechanism to ensure the UK cannot be a net beneficiary of programme funding, but does not protect the UK from inappropriate imbalance in the opposite direction, which is more likely. The UK’s success rate in Horizon 2020 has decreased significantly in recently years, creating considerable uncertainty about what financial return could be expected. A multi-billion Euro contribution over the lifetime of the programme would make participation very difficult for the UK to justify. There needs to be a way of limiting the contribution from the UK, or any other country associating to the programme to ensure this is reasonable.

The original vision for Horizon Europe was that the programme should be ‘open to the world’. This reflects the globally collaborative nature of research and has been a key strength of Horizon 2020. For this to continue to grow under Horizon Europe, a model for association that can attract a range of third countries is necessary. Finding an appropriate solution to this is therefore essential for the benefit of the programme itself and international cooperation.

• The UK and EU should build on the original spirit of the Horizon Europe programme by introducing a two-way correction mechanism for balancing substantial disparities between initial contributions and eventual receipts from the programme. This could be capped if necessary, or only apply if the disparity is greater than a certain amount, after administrative costs are accounted for. It should apply to all third countries seeking to associate to Horizon Europe.

3. Overseeing the correct use of programme funds
The UK should not consider oversight of the Horizon Europe programme from EU institutions to be a red line for the negotiations. These bodies play only a narrow role in ensuring grant conditions are met and money is spent correctly. This oversight only applies to those in receipt of EU funding, and has no impact on national laws, or citizens that are not involved with receiving grants. Those who are uncomfortable with this arrangement need not participate—there is no imposition on them. Moreover, Wellcome’s internal analysis has found no examples of the European Court of Justice arbitrating pre-competitive research disputes. Other countries such as the USA accept this EU oversight of research funding, and there is no reason for the UK not to follow suit.

• The UK should accept the need for EU institutions to oversee the correct use of programme funds. Existing Horizon 2020 agreements recognise this, and it is part of the EU’s research collaboration with countries such as the USA.

4. Mobility
Collaboration and the sharing of ideas continues to be vital in accelerating high quality research and is crucial for the success of the programme. It is therefore in the EU and the UK’s interest that research workers can easily travel and work to share their expertise. It is fundamental to the smooth functioning of the programme that reciprocal arrangements to support the mobility of people participating in Horizon Europe are introduced by both sides, and reasonable that references to incorporating suitable reciprocal mobility arrangements are made as part of an agreement.

The UK’s Global Talent Visa provides one good route for putting such arrangements into practice, as it links eligibility for the visa to recognised sources of funding, such as Horizon 2020, and has scope for including skilled technicians that are vital to supporting research work. The importance of researcher mobility is already recognised in the UK’s R&D roadmap.

• Both sides should accept that an agreement should refer to reciprocal mobility arrangements being in place to support the functioning of the programme, recognising the need for mobility of research workers in different roles and sectors.

5. Exploitation of results
It is reasonable to expect that as a third country the UK would no longer have the exact same rights as it did as a Member State. This is reflected in the Commission’s proposal by for example the limiting of voting rights. However, researchers in associated countries should be able to exploit research results wherever they see fit. The draft regulation establishing Horizon Europe is currently unclear on whether exploitation would be permissible outside Member States.

• The EU should clarify that results of research conducted in and/or with partners in associated countries are exploitable in those jurisdictions, as well as in Member States.
22 July 2020

Statement supported by:

The Irish Universities Association


Dr Marta Agostinho, EU-LIFE Coordinator, EU-LIFE
Prof. Ali Alavi, Director, Max Planck Institute for Solid State Research, Stuttgart, Germany and Professor of Theoretical Chemistry, Cambridge, UK
Prof. Rudolf Amann, Director, Max Planck Institute for Marine Microbiology, Bremen, Germany
Dr Alberto Francesco Anfossi, Secretary General of Fondazione Compagnia di San Paolo
Professor Antti Arjava, Secretary General Finnish Cultural Foundation
Association of Universities in the Netherlands
Prof. Werner Ballmann, Director emeritus, Max Planck Institute for Mathematics, Bonn, Germany
Dr. Jon Atli Benediktsson, Rector and President of the University of Iceland, Chair of the Icelandic Rectors´ Conference
Prof. Thomas Boehm, Director, Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany
Prof. Armin von Bogdandy, Director, Max Planck Institute for Comparative Public Law and International Law, Heidelberg, Germany
Prof. Tobias Bonhoeffer, Director, Max Planck Institute of Neurobiology, München-Martinsried, Germany and Professor Ludwig-Maximilians-Universität, München.
Prof. Stephan Borrmann, Director, Max Planck Institute for Chemistry, Mainz, Germany
Dr Tim Bradshaw, CEO, Russell Group
Prof. Nils Brose, Director, Max Planck Institute of Experimental Medicine, Göttingen, Germany and Professor, University of Göttingen, Germany
Aisling Burnand MBE, Chief Executive, Association of Medical Research Charities
Campaign for Science and Engineering
Cancer Research UK
Professor Victor van der Chijs, President European Consortium of Innovative Universities (ECIU), President University of Twente (NL)
Conference of Rectors of Academic Schools in Poland
Prof. Josef Drexl Director, Max Planck Institute for Innovation and Competition, München, Germany
Dr Mark Downs CSci FRSB, CEO, Royal Society of Biology
Professor Philippe Dubois, Rector, University of Mons – Belgium
Prof. Gregor Eichele, Director, Max Planck Institute for Biophysical Chemistry, Göttingen, Germany
Prof. Reinhard Faessler, Director, Max Planck Institute of Biochemistry, München-Martinsried, Germany
Prof. Simon E. Fisher, Director, Max Planck Institute for Psycholinguistics and Professor, Raboud University, Nijmegen, Netherlands
Prof. David Fitzpatrick, Director, Max Planck Florida Institute for Neuroscience, Jupiter, USA
Sir Jeremy Farrar, Director, Wellcome
Prof. Dr. Detlev Ganten, President of the World Health Summit
Pascal Garel, Chief Executive of HOPE – European Hospital and Healthcare Federation
Dr Matthias Girod, Secretary General, EuroScience
Prof. Helmut Grubmüller, Director, Max Planck Institute for Biophysical Chemistry, Göttingen, Germany
Prof. Jochen Guck, Director, Max Planck Institute for the Science of Light, Erlangen, Germany and Max-Planck-Zentrum für Physik und Medizin, Erlangen, Germany
Prof.dr.ir. Tim van der Hagen, Rector Magnificus, President Executive Board Delft University of Technology
Prof. Chris Hann, Director, Max Planck Institute for Social Anthropology, Halle(Saale), Germany and Fellow, Corpus Christi College, Cambridge, UK
Prof. Peter Hagoort, Director, Max Planck Institute for Psycholinguistics, Nijmegen, Netherlands
Prof. David G. Heckel, Director, Max Planck Institute for Chemical Ecology, Jena, Germany
Dr Marika Hedin, CEO, Riksbank’s Jubilee Fund Foundation
Prof. Stephan Herminghaus, Director, Max Planck Institute for Dynamics and Self-Organization, Göttingen, Germany
Prof. Pamela Kearns, President, SIOP Europe
Professor Rüdiger Klein, Director, Max Planck Institute of Neurobiology, Munich-Martinsried, Germany
Prof. Ferenc Krausz, Director, Max Planck Institute of Quantum Optics, Garching, Germany and Professor Physics Ludwig-Maximilians-Universität München, Germany
Professor Wolfram Koch, Executive Director German Chemical Society (GDCh)
Prof. Werner Kühlbrandt, Director, Max Planck Institute of Biophysics, Frankfurt (Main), Germany
Jesper Langergaard, Director, Universities Denmark
League of European Research Universities (LERU)
Professor Maria Leptin, Director, EMBO
Prof. Gerd Leuchs, Director emeritus, Max Planck Institute for the Science of Light, Erlangen, Germany
Dr David Llewellyn, Chair, Guild HE
Prof. Hartmut Michel, Director, Max Planck Institute of Biophysics, Frankfurt, Germany Nobel Prize Winner in Chemistry (1988)
Prof. Andrew Mackenzie, Director, Max Planck Institute for Chemical Physics of Solids, Dresden, Germany and Professor of Condensed Matter Physics, University of St Andrews, UK
Prof. Florian Marquardt, Director, Max Planck Institute for the Science of Light, Erlangen, Germany
Carlos Moedas, Trustee of the Calouste Gulbenkian Foundation, Former European Commissioner for Research, Science & Innovation
Professor Michael Murphy, President, European University Association
Prof. Andrea Musacchio, Director, Max Planck Institute of Molecular Physiology, Dortmund, Germany Chair, Biomedical Section, Max Planck Society
Dr Chaand Nagpaul CBE, British Medical Association Chair of Council
Prof. Frank Neese, Director, Max Planck Institut für Kohlenforschung, Mülheim/Ruhr, Germany
Sir Paul Nurse FRS Nobel Laureate for Physiology or Medicine 2001Prof. Kirpal Nandra, Director, Max Planck Institute for Extraterrestrial Physics, Garching, Germany and Professor Ludwig Maximilians University, München, Germany
Professor Dag Rune Olsen, President, Universities Norway
Prof. Joël Ouaknine, Director, Max Planck Institute for Software Systems, Kaiserlautern/Saarbrücken, Germany
Dr Helen Pain CSci CChem FRSC, Acting Chief Executive, Royal Society of Chemistry
Prof. Jan Palmowski, Secretary-General, The Guild of European Research-Intensive Universities
Prof. Dr. Martin Paul, President, Maastricht University
Professor Peter Piot, Director of the London School of Hygiene & Tropical Medicine
Silvia Gomez Recio, Secretary General, Young European Research Universities Network (YERUN)
Prof. Jürgen Renn, Director, Max Planck Institute for the History of Science, Berlin, Germany
Professor David Richardson, President of the Aurora University Network
Prof. Jan Michael Rost, Director, Max Planck Institute for the Physics of Complex Systems, Dresden, Germany
Prof. Angel Rubio, Director, Max Planck Institute for the Structure and Dynamics of Matter, Hamburg, Germany
Professor Sir Nilesh Samani, Medical Director, The British Heart Foundation
Teresa Sanjurjo, Director, Princess of Asturias Foundation
Dr Gerard M Salole, B.A., M.A.(Econ), Ph.D., F.R.A.I, Chief Executive, European Foundation Centre
Prof. Robert Schlögl, Director, Max Planck Institute for Chemical Energy Conversion, Mülheim/Ruhr, Germany and Director, Fritz-Haber-Institute of the Max-Planck-Society, Berlin, Germany
Prof. Dr. Andreas Schlueter, Secretary General Stifterverband für die Deutsche Wissenschaft
Prof. Hans Schöler, Director, Max Planck Institute for Molecular Biomedicine, Münster, Germany
Prof. Paul Schulze-Lefert, Director, Max Planck Institute for Plant Breeding Research, Cologne, Germany
Prof. Werner Seeger, Director, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany and Professor, University of Giessen/Marburg, Germany
Prof. Hans-Peter Seidel, Director, Max Planck Institute for Informatics, Saarbrücken, Germany
Prof dr Luc Sels, President, Flemish Interuniversity Council (VLIR)
Professor Karin Sipido, Department of Cardiovascular Sciences, KU Leuven
Professor Luc Soete, Honorary Professor of Economics, Maastricht University and Dean of the Institute of European Studies at VUB, Brussels
Prof. Joachim P. Spatz, Director, Max Planck Institute for Medical Research, Heidelberg, Germany and Professor, University of Heidelberg, Germany
Dr Mangala Srinivas, Chair, Young Academy of Europe
Prof. Mark Stitt, Director, Max Planck Institute of Molecular Plant Physiology, Potsdam, Germany
Dr David Strain, Co-Chair, British Medical Association Medical Academic Staff Committee
Professor Bart de Strooper, Director, UK Dementia Research institute, Joint Professor University College London and KUL, Leuven
UNICA, Network of Universities from the Capital of Europe
Universities UK
Dr Koen Verlaeckt, Secretary General, Flemish Interuniversity Council (VLIR)
Prof. Dietmar Vestweber, Director, Max Planck Institute for Molecular Biomedicine, Münster, Germany
Dr Greg Walker, Chief Executive MillionPlus, The Association for Modern Universities
Prof. Tristan Weddigen, Director, Bibliotheca Hertziana, Max Planck Institute for Art History, Rome, Italy
Prof. Detlef Weigel, Director, Max Planck Institute for Developmental Biology, Tübingen, Germany Foreign Member, Royal Society, London, UK
Professor Astrid Söderbergh Widding, President, Association of Swedish Higher Education Institutions (SUHF)
Prof. Alec M. Wodtke, Director, Max Planck Institute for Biophysical Chemistry, Göttingen, Germany
Rector Pierre Wolper, Chairman, CRef – Rectors’ Council of the French-Speaking Universities Belgium.
Prof Emilio Zagheni, Director, Max Planck Institute for Demographic Research, Rostock, Germany
Prof. J. Anton Zensus, Director, Max Planck Institute for Radio Astronomy, Bonn, Germany
Prof. Marino Zerial, Ph.D., Director, Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany